DMAAHIGH SIGNALFINANCIAL10-K

DMAA completed its IPO and experienced dramatic balance sheet expansion with total assets surging over 43,000% to $239.9M, though stockholders' equity deteriorated significantly to -$7.3M.

This represents the typical post-IPO transformation for a SPAC, with the massive asset increase reflecting IPO proceeds held in trust for future acquisitions. However, the negative stockholders' equity of -$7.3M and operating losses of -$2.8M indicate the company is burning through capital while searching for a merger target, creating time pressure to complete a business combination.

Comparing 2026-04-15 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial statements show a classic SPAC post-IPO profile with total assets exploding from $551K to $239.9M due to IPO proceeds, while the company shifted from a small net loss to $5.9M net income primarily from investment income on trust assets. However, operating performance deteriorated with operating losses expanding to -$2.8M and operating cash flow declining to -$539K, reflecting ongoing search costs and administrative expenses. The negative stockholders' equity of -$7.3M combined with increased liabilities signals the typical SPAC structure where most IPO proceeds are held in trust rather than on the balance sheet as equity.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+43456.4%
$551K→$239.9M

Asset base grew 43456.4% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
-2866.8%
-$245K→-$7.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
+2222.8%
-$280K→$5.9M

Net income grew 2222.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
-906.3%
-$280K→-$2.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
+814.5%
$796K→$7.3M

Liabilities grew 814.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
-213%
-$172K→-$539K

Operating cash flow fell 213% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Assets
Balance Sheet
+144.3%
$5K→$12K

Current assets grew 144.3% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-52.7%
$796K→$376K

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-31
ADDED
As of April 15, 2026, the registrant had 33,717,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to Drugs Made In America Acquisition LLC, our sponsor, an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Simultaneously with the closing of the IPO, we consummated the private placement with our sponsor of 400,000 units (the Private Placement Units ) at a price of $10.00 per unit, for $4,000,000.
There is no guarantee that our shareholders at the extraordinary general meeting will approve this proposal.
Recent Developments The ordinary shares and rights comprising the units began separate trading on February 25, 2025.
+7 more — sign up free →
REMOVED
As of March 28, 2025, the registrant had 33,517,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to the sponsor an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a pharmaceutical business in the United States.
Business Strategy Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry.
We believe our management team s knowledge, decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →